Home

Rachel K. King

CIK 1589712 · President, CEO · last filed 2026-07-02

Rachel K. King is a President, CEO who has filed 37 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing, for FULC, was dated Jul 2, 2026. Across all open-market trades the lifetime net is −$223.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $356.4K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$356.4K

Companies

3

Total Filings

37

Lifetime Open-Market Net

-$223.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FULC Director — $3.75 — $0 3 2026-07-02
NVAX Director 45,170 $7.89 $356.4K $105.9K 16 2026-06-23
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director 6,059 $15.70 $95.1K -$329.1K 17 2024-05-01

Recent Filings

37 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-02 FULC Grant (A) — $0 EDGAR
2026-06-23 NVAX Mixed +18,880 $0 EDGAR
2025-06-30 FULC Grant (A) — $0 EDGAR
2025-06-24 NVAX Grant (A) — $0 EDGAR
2025-06-13 NVAX Exer (M) +10,420 $0 EDGAR
2025-01-02 NVAX Sell (S) −4,150 -$37.4K EDGAR
2024-12-13 NVAX Notice (144) −4,150 -$37.4K EDGAR
2024-11-14 FULC Grant (A) — $0 EDGAR
2024-06-14 NVAX Mixed +6,670 $0 EDGAR
2024-05-01 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 37
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.